Merck’s stock suffering worst day in 3 years after profit outlook was cut

Merck’s stock took a dive Tuesday, after the drugmaker reported second-quarter profit and sales that beat expectations, amid strength in sales of cancer treatment Keytruda, but provided a mixed full-year outlook.